SII resumes Covishield exports under COVAX
The Hindu
Pharma major has exceeded production target of 1 billion doses for 2021
The Serum Institute of India (SII) on Friday officially announced that it has resumed exports of its COVID-19 vaccine Covishield under the international vaccine sharing programme COVAX.
The resumption of exports is linked to the SII surpassing its original target to produce one billion doses of Covishield by this year’s end, a statement issued by SII said, adding that it had reached this milestone ahead of time owing to the “rapid expansion of production capacity” at its Pune facility.
Earlier in the day, the first batches of Covishield left the SII manufacturing facility in Pune for distribution to low- and middle-income countries via the COVAX arrangement. SII’s supply of doses through COVAX is expected to increase substantially in the first quarter of next year, the statement added.